参考文献/References:
[1] Stangier J, Stahle H, Rathgen K,et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment[J]. J Clin Pharmacol, 2008, 48(12): 1411-1419.
[2] Liesenfeld K H, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial[J]. J Thromb Haemost, 2011, 9(11): 2168-2175.
[3] 屠莹,陈丽娟,王平. HPLC测定达比加群酯中的有关物质[J].中国现代应用药学,2016, 33(9): 1165-1170.
[4] Go AS, Hylek E M, Phillips K A, et al. Prevalence of diagnosed atrial fibrillation indults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation(ATRIA)study [J]. JAMA, 2001, 285(18): 2370-2375.
[5] Reilly P A, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients:the RE-LY trial(randomized evaluation of long-term anticoagulation therapy[J]. J Am Coll Cardiol, 2014, 63(4): 321-328.
[6] 孙敏,刘鹏,付晓丽,等. HPLC测定大鼠血浆中达比加群的浓度[J].中国新药杂志,2013, 22(10): 1206-1209,1221.
[7] 向志雄,马文狄,夏广新. Beagle犬血浆中达比加群的UPLC-MS/MS法测定[J].中国医药工业杂志,2015, 46(10): 1096-1099.
[8] 韩舒,谷元,张爱杰,等.高效液相色谱-串联质谱法测定大鼠血浆中的达比加群[J].中国临床药理学与治疗学,2015, 20(12): 1354-1359,1372.
[9] Delavenne X, Moracchini J, Laporte S, et al. UPLC MS/MS assay for routine quantification of dabigatran-a direct thrombin inhibitor-in human plasma [J]. J Pharm Biomed Anal, 2012, 58(1): 152-156.
相似文献/References:
[1]陈 敏 高红瑾 阳丽梅.HPLC-MS/MS法测定人血浆中利伐沙班的浓度[J].福建医药杂志,2019,41(06):145.
CHEN Min,GAO Hongjin,YANG Limei..Determination of rivaroxaban concentration in human plasma by HPLC-MS/MS[J].FUJIAN MEDICAL JOURNAL,2019,41(06):145.